I don’t necessarily view this as foot dragging by the FDA. I would have preferred a rubber stamp and move on but I really suspect the back and forth is related to the new protocol. A lot hangs on that protocol and up coming study and I would rather they get it right than get it quick…this is a nuanced study and the biomarkers and end points need to be very well thought out…Jay Lalezari would surely agree and work to ensure the study is well powered and well thought out. If this attention to detail with CD12 had taken place we would probably have been approved. We have suffered the emotional upheaval as a result of the company trajectory but I along with many here had the chance to acquire many more shares as a result. Good news bad news but good news is ahead when Leronlimab gets back on the dance floor.